TY - JOUR
T1 - What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis
AU - Van der Elst, Kristien
AU - Mathijssen, Elke G. E.
AU - Landgren, Ellen
AU - Bremander, Ann
AU - De Groef, An
AU - Lindqvist, Elisabet
AU - Nylander, Maria
AU - Peters, Alma
AU - Van den Hoogen, Frank
AU - van Eijk-Hustings, Yvonne
AU - Verhoeven, Gerard
AU - Vriezekolk, Johanna E.
AU - Westhovens, Rene
AU - Larsson, Ingrid
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020/9
Y1 - 2020/9
N2 - Objectives To explore treatment outcomes preferred by patients with early rheumatoid arthritis (RA) and how these change throughout the early disease stage across three European countries. Methods A longitudinal, qualitative, multicentre study was conducted in Belgium, the Netherlands and Sweden. 80 patients with early RA were individually interviewed 3-9 months after treatment initiation and 51 of them participated again in either a focus group or an individual interview 12-21 months after treatment initiation. Data were first analysed by country, following the Qualitative Analysis Guide of Leuven (QUAGOL). Thereafter, a meta-synthesis, inspired by the principles of meta-ethnography and the QUAGOL, was performed, involving the local research teams. Results The meta-synthesis revealed 11 subthemes from which four main themes were identified: disease control, physical performance, self-accomplishment and well-being. 'A normal life despite RA' was an overarching patient-preferred outcome across countries. Belgian, Dutch and Swedish patients showed many similarities in terms of which outcomes they preferred throughout the early stage of RA. Some outcome preferences (eg, relief of fatigue and no side effects) developed differently over time across countries. Conclusions This study on patient-preferred outcomes in early RA revealed that patients essentially want to live a normal life despite RA. Our findings help to understand what really matters to patients and provide specific insights into the early stage of RA, which should be addressed by clinicians of different disciplines from the start of treatment onwards.
AB - Objectives To explore treatment outcomes preferred by patients with early rheumatoid arthritis (RA) and how these change throughout the early disease stage across three European countries. Methods A longitudinal, qualitative, multicentre study was conducted in Belgium, the Netherlands and Sweden. 80 patients with early RA were individually interviewed 3-9 months after treatment initiation and 51 of them participated again in either a focus group or an individual interview 12-21 months after treatment initiation. Data were first analysed by country, following the Qualitative Analysis Guide of Leuven (QUAGOL). Thereafter, a meta-synthesis, inspired by the principles of meta-ethnography and the QUAGOL, was performed, involving the local research teams. Results The meta-synthesis revealed 11 subthemes from which four main themes were identified: disease control, physical performance, self-accomplishment and well-being. 'A normal life despite RA' was an overarching patient-preferred outcome across countries. Belgian, Dutch and Swedish patients showed many similarities in terms of which outcomes they preferred throughout the early stage of RA. Some outcome preferences (eg, relief of fatigue and no side effects) developed differently over time across countries. Conclusions This study on patient-preferred outcomes in early RA revealed that patients essentially want to live a normal life despite RA. Our findings help to understand what really matters to patients and provide specific insights into the early stage of RA, which should be addressed by clinicians of different disciplines from the start of treatment onwards.
KW - Arthritis
KW - Health Care
KW - Outcome and Process Assessment
KW - Qualitative research
KW - Rheumatoid
KW - CRITERIA
KW - MODIFYING ANTIRHEUMATIC DRUGS
KW - MANAGEMENT
KW - PERSPECTIVE
KW - EUROPEAN LEAGUE
KW - RECOMMENDATIONS
KW - PEOPLE
KW - LIFE
KW - REMISSION
U2 - 10.1136/rmdopen-2020-001339
DO - 10.1136/rmdopen-2020-001339
M3 - Article
C2 - 32938747
SN - 2056-5933
VL - 6
JO - RMD Open
JF - RMD Open
IS - 2
M1 - 001339
ER -